Aunque los agonistas GLP-1 tienen bajo riesgo intrnseco de hipoglucemia, la terapia combinada aumenta este riesgo
Patel A, ADVANCE Collaborative Group, MacMahon S, ADVANCE Collaborative G, MacMahon S, Chalmers J, et al
There are specific circumstances in which professional advice is particularly important: Before starting any new supplement whilst enrolled in a clinical trial or taking a GLP-1 medicine, as this may affect trial validity or treatment safety If you have diabetes , as retatrutide has glucose-lowering properties and, if you are also taking insulin or a sulfonylurea, the risk of hypoglycaemia requires careful management If you have liver or kidney disease , since both NAD+ metabolism and retatrutide's glucagon-mediated actions involve hepatic pathways
This hormone communicates with the hypothalamus, the brains appetite control centre, to reduce hunger and food-seeking behaviour